Bilateral intraocular inflammation after intravitreal bevacizumab in Behcet's disease.
Bae
J H
JH
Lee
S C
SC
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000867:Anterior Chamber; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001528:Behcet Syndrome / Q000188:drug therapy*; D000068258:Bevacizumab; D005128:Eye Diseases / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy; D058449:Intravitreal Injections; D008297:Male; D016896:Treatment Outcome; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000068258:Bevacizumab